3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
127
Carcinoma, Non-Small-Cell Lung
57
Squamous Cell Carcinoma of Head and Neck
46
Neoplasms
41
Head and Neck Neoplasms
38
Neoplasm Metastasis
31
Pancreatic Neoplasms
15
Colonic Neoplasms
14
Lung Neoplasms
13
Carcinoma, Squamous Cell
13
Breast Neoplasms
13
Rectal Neoplasms
12
Recurrence
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Ovarian Neoplasms
8
Melanoma
7
Stomach Neoplasms
6
Carcinoma, Renal Cell
6
Carcinoma
6
Solid Tumors
5
Gastrointestinal Neoplasms
5
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Sarcoma
4
Neoplasms, Squamous Cell
4
Laryngeal Diseases
4
Advanced Solid Tumor
4
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Pancreatic Ductal
3
Uterine Cervical Neoplasms
2
Interventions
Vinorelbine
1
Temozolomide
1
Radiotherapy
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metatropic dwarfism
×
Cetuximab
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts